Recently Featured

BioDuro Enters Taiwan Joint Venture, Adding Commercial API Plant to Production Network

March 16, 2026
BioDuro, headquartered in California, has established a joint venture with Taiwan-based Cenra API Solutions, integrating Cenra’s commercial-scale facility in Taipei into its production network. This strategic move is designed to enhance BioDuro’s capabilities in the rapidly evolving pharmaceutical manufacturing landscape. The partnership not only expands BioDuro’s geographical footprint but also strengthens its position in the…

FDA Grants Vanda Pharmaceuticals a Hearing on Jet Lag Drug Approval After Years of Advocacy

March 16, 2026
The U.S. Food and Drug Administration (FDA) has responded to Vanda Pharmaceuticals’ persistent requests for a public hearing regarding the proposed expansion of its Hetlioz label to include treatment for jet lag. This development comes after the drug was initially rejected in 2019, marking a significant moment for the company that has sought to address…

HUTCHMED initiates global trial of novel attc therapy HMPL-A580 for solid tumors

March 16, 2026
HUTCHMED has commenced a first-in-human phase 1/2a clinical trial of its novel antibody-drug conjugate (ADC) therapy, HMPL-A580, targeting advanced solid tumors. This pivotal study is being conducted in both China and the United States, marking a significant step in the development of innovative cancer treatments. The launch of this trial comes at a time when…

Wildfire Pollution Linked to Higher Stroke Risk

March 16, 2026
Recent studies have established a significant correlation between wildfire pollution and an increased risk of stroke. As wildfires become more frequent and intense due to climate change, the resultant air quality deterioration poses severe health risks, particularly for vulnerable populations. This alarming trend underscores the urgent need for regulatory bodies and public health officials to…

Ongoing Cases